ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD79b Antibody-drug Conjugate SHR-A1912

Also written as “SHR-A1912; R-Chemo”, “SHR-A1912 Injection” and “SHR-A1912”.

In Jiangsu HengRui Medicine’s pipeline, CD79b ADC. Its studies are mostly in Lymphoma, B-Cell · Lymphoma, Large B-Cell, Diffuse, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Apr 8, 20253 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine33 open or runningphase 3since Apr 8, 2025Nov 5, 2021Mar 2027phase 3 · NCT06929624
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-A1912, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2021First study: phase 1 study in Lymphoma, B-CellFirst studyNCT05113069 · 170 planned · China
  2. Oct 23, 2023Phase 2 study in Lymphoma, B-CellNCT06104553 · 132 planned · China
  3. Apr 8, 2025Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06929624 · 282 enrolled · China

Ahead

  1. Mar 2027Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06929624

TargetBeta

“CD79b ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29) conjugated to a topoisomerase-1 inhibitor, with potential antineoplastic activity. …”NCIt, read by Claude

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06929624Lymphoma, Large B-Cell, Diffuse · China3Active, not recruitingMar 2027282
NCT06104553Lymphoma, B-Cell · China2RecruitingDec 2025132
NCT05113069Lymphoma, B-Cell · China1By invitationMar 31, 2024170

How it is read

Names in the registry

  • “SHR-A1912; R-Chemo”, 2 entries
  • “SHR-A1912 Injection”, 1 entry
  • “SHR-A1912”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.